Immedica Pharma to Acquire Marinus Pharmaceuticals in Cash Deal Worth $151 Million

Immedica Pharma AB entered a merger agreement on December 30, 2024, to acquire Marinus Pharmaceuticals, Inc. (MRNS) through a tender offer of about $151 million.

Deal Structure:

Under the terms of the agreement, Immedica, through a wholly owned, direct subsidiary, will initiate a tender offer to acquire all the outstanding shares of Marinus common stock for a cash purchase price of $0.55 per share, representing a premium of 48.65% from the stock’s last close.

Company Profile:

Marinus is a pharmaceutical company focused on developing and commercializing innovative therapies for seizure disorders and rare genetic epilepsies, including ZTALMY, an FDA-approved treatment for CDKL5 deficiency disorder.

Immedica is a Stockholm-based pharmaceutical company specializing in the commercialization of medicines for rare diseases and specialty care, serving patients in over 50 countries.

Deal Details and Timeline:

The acquisition will add Marinus’ ZTALMY (ganaxolone) oral suspension to Immedica’s global rare disease business. ZTALMY is a medication that works on the brain’s GABA-A receptors to help control seizures. The U.S. FDA approved it in March 2022 to treat seizures caused by CDKL5 deficiency disorder (CDD) in patients aged two and older.

The deal is expected to close in Q1 2025.

“By adding ZTALMY to our portfolio, we will expand our presence in the United States, .. to deliver impactful therapies for underserved patient populations,” said Anders Edvell, the Chief Executive Officer of Immedica.

Immedica is acquiring Marinus at 0.95 times sales.

Deal Metrics:

To get a more comprehensive understanding of this merger and acquisition transaction, please visit the Deal Metrics page:

Deal Metrics for the acquisition of Marinus Pharmaceuticals, Inc. (MRNS) by Immedica Pharma AB

The Deal Metrics page for each merger or acquisition includes:

• A spread history chart illustrating the merger’s progression from announcement through eventual execution or failure.
• A timeline of key events such as the expiration of the HSR period, regulatory approvals, shareholder votes, etc.
• News and SEC filings related to the merger.
• A history of deal updates.
• Plus much more.

Disclaimer: Please exercise due diligence before buying or selling any securities mentioned in this article. We do not warrant the completeness or accuracy of the content or data provided in this article.

Editor’s Note: Baranjot Kaur contributed to this article